2019 Programme

The Reception | 18:30 - 21:00 | Wednesday 8th May

The Wellcome Collection, 183 Euston Road, London NW1 2BE

____________________________________________________________________

The Conference |  08:15 - 18:30 | Thursday 9th May 

Add agenda items to your meeting schedule: click here.

8:15    Registration opens, full continental breakfast is served

9:00    Welcome 

 Mattias Johansson, Director, Ezenze Ltd, Anglonordic Conference Founder 

Morning session Chaired by Mary Clark, Managing Director, Optimum Strategic Communications

9:05    Keynote: Gil Bar-Nahum, Managing Director, EMEA Head of Biotechnology, Jefferies

9:30   Investor Panel - What’s hot and what's simmering?

Panel discussion on Investment trends, chaired by Lisa Urquart, Editor, EP Vantage

Speakers include:

  •  Hakan Goker, Senior Investment Director, M Ventures
  •  Stephan Christgau, Senior Partner, Novo Seeds
  •  Henrijette Richter, Managing Partner, Sofinnova
  •  Roel Bulthuis, Managing Director, INKEF Capital

10:30   Coffee

11:00   Company Presentations

Biotech Investment Room and Technology Room
Presentations include: 

  • Heinz Lubenau, VAXIMM
  • Søren Weis Dahl, Prophylix Pharma
  • Andrew Woodland, In4Derm, University of Dundee
  • Harri Sihto, Sartar Therapeutics
  • Magnus Strandh, Adenium Biotech
  • Aidan Courtney, Censo Biotechnologies
  • Sally Waterman, Medherant
  • Clare Wareing, Cumulus Oncology
  • Dorte Gram, Pila Pharma
  • Ursula Gompels, Virokine Therapeutics
  • George Frodsham, MediSieve
  • Ole Wiborg, Zerion

____________________________________________________________________

12:30 - 13:30    Networking Lunch

____________________________________________________________________

Afternoon session Chaired by Eva Haas, Senior Consultant, Optimum Strategic Communications

13:30    Technologies and treatments - What’s on the horizon?

Panel Discussion, chaired by Lucie Ellis, Editor, In Vivo

Speakers include:

  •  Niall Martin, CEO, Artios Pharma
  •  Ian Wilson, CEO, ImaginAB
  •  Sue Herbert, Head of Strategy, Merck
  •  Dirk Beher, CEO and Founder, Asceneuron SA

14:30    Company Presentations

Biotech Investment Room and Technology Room
Presentations include: 

  • Michael Hunt, ReNeuron
  • Andreas Kungl, Antagonis Biotherapeutics
  • Gerben Moolhuizen, ISA Pharma
  • Povl Verder, SIME Clinical AI
  • David Brooks, Ablatus
  • Lars-Erik Eriksson, CLS AB
  • Christian Jorgensen, Biotec Pharmacon
  • Thomas Holm Pederson, NMD Pharma A/S
  • Albert A. Luderer, Indi Molecular
  • Noor Shaker, GTN Ltd

15:45    Coffee

16:00    Challenges and opportunities for Women in European Biotech and Medtech

Panel Discussion, Chaired by Eleanor Malone, Editor, Scrip

Speakers include:

  • Anne Marieke Ezendam, Senior Consultant, Optimum Strategic Communications, ex-Fund Manager
  • Renee Aguiar-Lucander, CEO, Calliditas
  • Hayley French, CEO, Apitope
  • Ingeborg Oie, CFO, CMR Surgical

16:45   If I knew then what I know today

Panel Discussion chaired by Mike Ward, Chief Content Officer, Datamonitor Healthcare & Scrip Intelligence

Speakers include:

  • Anker Lundemose, CEO, Mission Therapeutics
  • Edwin Moses, Chairman, Serial entrepreneur and value creator
  • Louise Makin, CEO, BTG
  • Ian Nicholson, CEO, F2G

17.45    Conclusions

17.55 - 18:45   Drinks Reception

Hosted by Mattias Johansson, Director, Ezenze Ltd

____________________________________________________________________

1:1 meetings take place throughout the day and are pre-booked online. 

Login to add your profile, bookmark prospects and book meetings.

____________________________________________________________________

Attendees
73 Investors:
4BIO Capital, Abingworth, Advent Life Sciences, Albion Technology & General VCT, ALSA Holdings, Amadeus Capital Partners, Anvil Partners, Arix Bioscience, Arrowfield Capital, Axilium Capital, Bioscience Managers, BioSeed Capital, Bridge Valley Ventures, Catapult Ventures, Curam Capital Management, DeBere Capital Partners, Deltec International Group, FastVentures, GGS Associates, Glentworth Ventures, Hayfin Capital Management, Helsinn Investment Fund, Ignite Capital Partners, Industrifonden, INKEF Capital, Inkef Capital, Innovator Capital, Inventages Venture Capital, Investor Corporat, IP Group, IPF Partners, JJDC, Julz Co, LifeArc Seed Fund, Longacre Funding partners, LSP, M Ventures, Masselos Family Office, MEDICXI, Mercia Technologies, Molecular Warehouse, Momentum Biotech, MVM Partners, National Institute for Health Research, NCL Technology Ventures, Newable Private Investing, New Science Fund, Norgine Ventures, Novo Seeds, Novo Ventures, NVM, Optum Ventures, Panakes Partners, Rosetta Capital, Rothschild, S.R.One, SBA, Seroba Life Sciences, Seventure, Sofinnova, Start Codon, Sunstone Life Science Ventures, The Cure Parkinson's Trust, Trillium Medical Ventures, UCL Technology Fund, UKI2S, Velocity Fund Partners, Vivanova.
Delegates: Abbvie, Ablatus Therapeutics, Artios Pharma, AstraZeneca, Bayer, Eli Lilly, Johnson and Johnson Innovation, Merck, Otsuka Europe, Ablatus Therapeutics, Acesion Pharma, Adenium Biotech, Antagonis, Apitope, Arcus Altor, Arterial Capital Management, Artios Pharma, Asceneuron, Athena Market Access Solutions, AVILLION, BioCentury Publications, BioPartner UK, Biotec Pharmacon, BTG, Calliditas, Censo Biotechnologies, CLS AB, CMR Surgical, COMPASS Pathways, Cord Communications, Cumulus Oncology, Department for International Trade, DeSaque, DMNoMore, Drug Discovery Today, Embassy of Denmark, Embassy of Spain in London, Enzyre, EP Vantage, Eurofins Amatsigroup, Eurofins Selcia, Evox Therapeutics, Ezenze, F2G, Forendo Pharma, Fusion Antibodies, Global Regulatory Services, GTN Ltd, ImaginAB, Indi Molecular, International Biotechnology Trust, Invest in Denmark, ISA Therapeutics, Ixico, J A Kemp, Jefferies, Labiotech.eu, London Business School, LSX, Masters Speciality Pharma, Medherant, Medicon Valley Alliance, MediSieve, MediWales, Meeting Mojo, Mission Therapeutics, Nature Biotechnology, Neophore, NMD Pharma, Novintum Bioscience, One Nucleus, Optimum Strategic Communications, Orbit Discovery, Owkin, Oxford Cardiomox, Parkinson’s Concierge, PCI Clinical Services, Pebmond Associates, PharmaNetwork Magazine, Pharma Publications, Precision Medicine Oncology & Rare Disease, Prophylix, Public Health England, Random42, RDP Life Sciences, ReNeuron, River Stone, RTC S.p.A., RYSE Asset Management, Sartar Therapeutics, Scrip, Silicon Valley Bank, SIME Clinical AI, Spencer Stuart, Sygnature Discovery, UK BioIndustry Association (BIA), University of Dundee, VAXIMM, Verdict, Virokine Therapeutics, William Reed, Xenogesis, Zerion.